AI drug synthesis is moving from early promise to practical lab support. New research in March 2026 described a machine learning workflow built for asymmetric cross-coupling, a reaction class widely used in drug development. The system predicts how catalysts, ligands and substrates will combine to favor the desired molecular handedness, which matters because mirror-image forms can behave differently in the body.
The workflow was trained on sparse experimental data from four academic papers using nickel-based catalysts and different ligands. It was then tested on increasingly unfamiliar hypothetical reaction components, with the goal of making useful predictions for reactions the model had not previously seen. In one reported example, researchers said the tool cut experimental screening from roughly 50-60 reactions to about 5-10, reducing both time and material use.
A second advance addresses another bottleneck in AI drug synthesis: turning promising ideas into compounds that can actually be made. The open-source MOSAIC platform was reported in January 2026 as a way to navigate millions of reaction protocols and the hundreds of thousands of new reactions added each year. Researchers said MOSAIC helped realize more than 35 new compounds, with a 71% success rate in experimental validation.
Taken together, these tools point to a more efficient chemistry workflow – one system helps decide which reactions to run, while another helps map viable synthesis routes after a target is chosen.
